Henan Lingrui Pharmaceutical Co., Ltd.

600285

CNE000001501

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
25.3 ^CNY	+8.68%		+7.75%	+47.87%

Apr. 25	Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 25	Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Henan Lingrui Pharmaceutical Co., Ltd. authorizes a Buyback Plan.

February 31, 2021

The Board of Directors of Henan Lingrui Pharmaceutical Co., Ltd. has authorized a buyback plan on February 1, 2021.

Latest news about Henan Lingrui Pharmaceutical Co., Ltd.

Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Henan Lingrui Pharma Registers Chewable Asthma Drug in China	Apr. 19	MT
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-09	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-05	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-25	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-25	CI
Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback announced on February 1, 2022 has expired with 19,086,325 shares, representing 3.39% for CNY 184.47 million.	22-01-30	CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.	22-01-03	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.	21-10-07	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-30	CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.	21-07-02	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-27	CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.	21-04-01	CI
Henan Lingrui Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	21-02-01	CI
Henan Lingrui Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	21-01-31	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-27	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-17	CI
Henan Lingrui Pharmaceutical Co., Ltd. Announces Cash Dividend for 2019, Payable on June 19, 2020	20-06-11	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-28	CI

Chart Henan Lingrui Pharmaceutical Co., Ltd.

Duration

Period

Chart Henan Lingrui Pharmaceutical Co., Ltd.

More charts

Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.

Sector

Pharmaceuticals

Calendar

2024-05-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Henan Lingrui Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.3

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B
DONG-E-E-JIAO CO.,LTD.	+35.04%	5.92B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+33.40%	1.38B

Alternative Medicine